White Papers

An Innovation Roadblock: The Shrinking Availability of Venture Capital in MedTech

Posted January 19, 2018| Prem Meyyan

The medical device sector, like many health segments, is driven by the usual suspects: a growing elderly population, rising prevalence of debilitating diseases, increased importance on quality-of-life, and innovation through painstaking research and development (R&D) efforts.

R&D is the only factor that industry players have any influence over and presents significant potential to cause a paradigm shift in the medical device innovation we introduce and overall, how we approach the treatment and management of diseases via MedTech. By extension, innovation, whether in technological hardware or software or other key elements, could drive explosive growth across numerous product segments. What’s the challenge, then? In a word: funding.

Our health + life science consulting group investigated why innovation is stymied by lack of funding. Download the whitepaper to learn more.

Download the Whitepaper:



Tags: , , , , ,

Related Resources

Read More

Fuld + Company’s Initial Perspectives on the Impact of Covid-19: Emerging Opportunities Across Industries

After several weeks of observing and examining the actions of businesses, government and other participants in the U.S economy, Fuld […]

Read More

2019 Pharma Companies to Watch Report

This proprietary qualitative analysis identifies five top pharmaceutical companies that stand out as major disruptors. Fuld + Company’s analysis includes […]

Read More

Competitive Intelligence (CI) Dictionary

Competitive Intelligence is the collection and analysis of information to anticipate competitive activity, see past market disruptions and dispassionately interpret […]

Subscribe to our mailing list for our latest updates: